• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Vermont













Ah, a smug answer... nice. You understand that the question would not be asked if your "projections" added up to the physical scripts I've actually seen, right?

Please take my response at face value, not smugness. I am stating the same thing that you are implying. I'm on your side mate. Smug would be if I said to stop buying our poor data knowing full well that won't happen.